ALG-093578

ALG-093578 is an orally administered, liver-targeted small molecule inhibitor of programmed death-ligand 1 (PD-L1), developed by Aligos Therapeutics for the treatment of chronic hepatitis B (CHB). The compound is designed to enhance the immune response against the hepatitis B virus by blocking the PD-1/PD-L1 inhibitory pathway, thereby reversing T-cell exhaustion and restoring the activity of HBV-specific T cells. A key feature of ALG-093578 is its high liver specificity, which aims to provide potent local immunotherapy while minimizing the systemic immune-related adverse events typically associated with antibody-based checkpoint inhibitors like nivolumab or durvalumab.